search
Back to results

Omega Loop Versus Roux-en-Y Gastric Bypass (YOMEGA)

Primary Purpose

Obesity

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Laparoscopic Mini-gastric bypass
Procedure of reference in bariatric surgery
Sponsored by
Hospices Civils de Lyon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Obesity -, Bariatric surgery, Gastric bypass

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged between 18 and 65 years old
  • Morbid obesity with BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 associated with one or more co-morbidities (type 2 diabetes, arterial hypertension, sleep apnea, dyslipidemia, arthritis)
  • Patient who has benefited from an upper GI endoscopy with biopsies
  • Patient who has benefited from a pluridisciplinary evaluation, with a favorable opinion for a gastric bypass
  • Patient who understands and accepts the need for a long term follow-up
  • Patient who agrees to be included in the study and who signs the informed consent form
  • Patient affiliated to a healthcare insurance plan

Exclusion Criteria:

  • History of esophagitis on upper GI endoscopy (Los Angeles classification)
  • Severe gastroesophageal reflux disease (GERD), resistant to medical treatment
  • Presence of dysplastic modifications of the gastric mucosa or a history of gastric cancer, on upper gastrointestinal endoscopy.
  • Presence of Helicobacter Pylori resistant to medical treatment
  • Presence of an unhealed gastro-duodenal ulcer or an ulcer diagnosed less than 2 months previously
  • History of previous bariatric surgery (gastric band, sleeve gastrectomy, vertical banded gastroplasty)
  • Presence of a severe and evolutive life threatening pathology, unrelated to obesity
  • Presence of chronic diarrhea (≥ 3 loose or liquid stools per day, over a period of more than 4 weeks)
  • Pregnancy or desire to be pregnant during the study
  • Binge eating disorders or other eating disorders according to DSM V criteria
  • Mentally unbalanced patients, under supervision or guardianship
  • Patient who does not understand French/is unable to give consent
  • Patient not affiliated to a French or European healthcare insurance
  • Patient who has already been included in a trial which has a conflict of interests with the present study

Sites / Locations

  • Clinique Universitaire de Chirurgie Digestive et de l'Urgence - CHU de Grenoble
  • Cabinet de chirurgie générale, digestive et de l'obésité - Hôpital Privé Drôme et Ardèche
  • Service de Chirurgie Générale et Endocrinienne - Hôpital Claude Huriez - CHU de Lille
  • Service de Chirurgie Digestive - Hôpital Edouard Herriot - Hospices Civils de Lyon
  • Service de Chirurgie Digestive et Hépato-Bilio-Pancréatique et Transplantation Hépatique - Hôpital de la Pitié Salpêtrière
  • Service de Chirurgie Digestive, Générale et Cancérologique - Hôpital Européen Georges Pompidou - APHP
  • Service de Chirurgie Générale - Hôpital Privé de la Loire
  • Service de Chirurgie Digestive et Hépato-Biliaire-Centre Hospitalier Privé Saint Grégoire
  • Service de Chirurgie Générale, Digestive et Viscérale - Centre Hospitalier Intercommunal de Poissy / Saint Gerrmain en Laye

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Laparoscopic Omega Loop Bypass

Laparoscopic Roux-en-Y Gastric ByPass

Arm Description

Laparoscopic Mini-gastric bypass

Procedure of reference in bariatric surgery

Outcomes

Primary Outcome Measures

Weight loss assessment according to Excess BMI Loss percentage (EBL%)
Weight loss assessment according to Excess BMI Loss percentage (EBL%), calculated using the following formula: ((BMI 2 years after surgery - initial BMI) / (initial BMI - 22.5)) X 100

Secondary Outcome Measures

Weight loss according to absolute weight loss (aWL in kg), Excess Weight Loss percentage (EWL%), EBL%
Waist size reduction according to absolute waist size (in cm)
Medical and surgical complication rates
Medical and surgical complication rates (anastomotic leaks, biliary reflux, bowel obstruction, anastomotic ulcers, anastomotic stenosis, internal hernia, chronic gastritis, esophagitis, iron deficiency anemia …)
Type and severity of complications
Type and severity of early and late complications for each procedure, according to the Dindo-Clavien classification
Operative time
Operative time (expressed in minutes)
Mean length of stay
Mean length of stay based on the number of days of hospitalization from surgery (Day of surgery = D0) until the end of hospitalization
Patient's quality of life
Patient's quality of life score according to the IWQOL questionnaire and the BAROS questionnaire adapted to bariatric surgery
Metabolic and lipid profile
Metabolic profile of glucose homeostasis and the lipid profile according to antidiabetic and anitilipidemic treatments, HbA1c level, fasting glycemia, HDL, LDL and TG.
Dumping syndrome and hypoglycemia symptoms
Dumping syndrome and hypoglycemia symptoms will be assessed using the Sigstad questionnaire
Gastroesophageal reflux
Gastroesophageal reflux assessed by items 5 and 27 of the GIQLI questionnaire
Modifications of the gastric and esophageal mucosa
Histological modifications of the gastric and esophageal mucosa, based on upper GI endoscopy with biopsies
Frequency of diarrhea
Frequency of diarrhea based on items 7, 30, 31 and 36 of the GIQLI questionnaire
Nutritional status
Nutritional status, assessed by PTH, vitamin B1, B9, B12, and D levels before and 12 and 24 months after surgery and assessed by hemoglobin, albumin, prealbumin, ferritin, saturation coefficient, before and 6, 12 and 24 months after surgery .

Full Information

First Posted
May 12, 2014
Last Updated
April 24, 2018
Sponsor
Hospices Civils de Lyon
search

1. Study Identification

Unique Protocol Identification Number
NCT02139813
Brief Title
Omega Loop Versus Roux-en-Y Gastric Bypass
Acronym
YOMEGA
Official Title
Prospective Multicentric Randomized Trial of Efficiency and Safety of Laparoscopic Omega Loop Bypass Versus Roux-en-Y Gastric Bypass
Study Type
Interventional

2. Study Status

Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
May 2014 (Actual)
Primary Completion Date
March 2018 (Actual)
Study Completion Date
March 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Several prospective trials and metaanalysis have demonstrated the superiority of bariatric surgery on the medical treatment of obesity. The Roux-en-Y Gastric ByPass (RYGBP) procedure has been practiced for more than 30 years, and is the procedure of choice for morbidly obese with metabolic disorders in most of the reference centers. Nevertheless, the RYGBP is a technically demanding procedure with a learning curve of more than 75 cases. The complication rate is around 10% in expert centers. More recently another procedure has been described which seems as efficient on weight loss and co-morbidities as the RYGBP, with the advantage of being less technically difficult and less morbid, especially for multi-complicated obese and/or the super obese. It consists of a unique gastro-jejunal anastomosis between a long gastric pouch and a jejunal Omega loop. However, this procedure could be at risk of biliary reflux and anastomotic ulcers with dysplastic changes of the gastric and esophageal mucosa. As a result, the Omega loop bypass (OLB) has only been developed by a few teams and remains a controversial subject, particularly as only one monocentric randomized trial has compared it to the RYGBP, which is remains the gold standard. The first litterature results show similar or even better weight loss efficiency than RYGBP with a better feasibility. The early complication rate seems lower, but there are still insufficient data on long term morbidity and biliary reflux consequences. By performing a randomized and prospective comparison of OLB to RYGBP, the aim of the investigators study is to analyze the weight loss efficiency, the morbidity and mortality, the feasibility, and the quality of life of both techniques, in order to validate the Omega loop bypass as a procedure of choice in bariatric surgery Hypothesis : The OLB, while being as efficient as RYGBP on weight loss and metabolic complications, could be less morbid.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity -, Bariatric surgery, Gastric bypass

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
256 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Laparoscopic Omega Loop Bypass
Arm Type
Experimental
Arm Description
Laparoscopic Mini-gastric bypass
Arm Title
Laparoscopic Roux-en-Y Gastric ByPass
Arm Type
Active Comparator
Arm Description
Procedure of reference in bariatric surgery
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic Mini-gastric bypass
Intervention Description
The laparoscopic Omega Loop Bypass will consist of: a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His a narrow gastric tube will be calibrated to be approximately 1.5 cm wide an Omega loop of 200 cm a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler
Intervention Type
Procedure
Intervention Name(s)
Procedure of reference in bariatric surgery
Intervention Description
The laparoscopic Roux-en-Y Gastric Bypass will consist of: a small gastric pouch (about 30cc) an antecolic alimentary limb a gastro-jejunal anastomosis using a linear stapler a 150cm long alimentary limb a 50cm biliary limb a latero-lateral jejuno-jejunal anastomosis closure of the mesenteric defects
Primary Outcome Measure Information:
Title
Weight loss assessment according to Excess BMI Loss percentage (EBL%)
Description
Weight loss assessment according to Excess BMI Loss percentage (EBL%), calculated using the following formula: ((BMI 2 years after surgery - initial BMI) / (initial BMI - 22.5)) X 100
Time Frame
2 years after surgery
Secondary Outcome Measure Information:
Title
Weight loss according to absolute weight loss (aWL in kg), Excess Weight Loss percentage (EWL%), EBL%
Time Frame
1, 3, 6, 12, 18 and 24 months after surgery
Title
Waist size reduction according to absolute waist size (in cm)
Time Frame
1, 3, 6, 12, 18 and 24 months after surgery
Title
Medical and surgical complication rates
Description
Medical and surgical complication rates (anastomotic leaks, biliary reflux, bowel obstruction, anastomotic ulcers, anastomotic stenosis, internal hernia, chronic gastritis, esophagitis, iron deficiency anemia …)
Time Frame
1, 12 and 24 months after surgery
Title
Type and severity of complications
Description
Type and severity of early and late complications for each procedure, according to the Dindo-Clavien classification
Time Frame
During the month following surgery (for early complications) and from one month to 24 months postoperatively (for late complications)
Title
Operative time
Description
Operative time (expressed in minutes)
Time Frame
Recorded on the day of surgery (Day 0)
Title
Mean length of stay
Description
Mean length of stay based on the number of days of hospitalization from surgery (Day of surgery = D0) until the end of hospitalization
Time Frame
Average period of 5 days from surgery (Day of surgery = D0) until the end of hospitalization, recorded on Visit 4 (Month1 +/- 10 days)
Title
Patient's quality of life
Description
Patient's quality of life score according to the IWQOL questionnaire and the BAROS questionnaire adapted to bariatric surgery
Time Frame
The day before surgery (D-1) and 6, 12 and 24 months after surgery
Title
Metabolic and lipid profile
Description
Metabolic profile of glucose homeostasis and the lipid profile according to antidiabetic and anitilipidemic treatments, HbA1c level, fasting glycemia, HDL, LDL and TG.
Time Frame
During the period of inclusion (D-60 to D-2) and at 6, 12 and 24 months after surgery
Title
Dumping syndrome and hypoglycemia symptoms
Description
Dumping syndrome and hypoglycemia symptoms will be assessed using the Sigstad questionnaire
Time Frame
At 1, 3,6,12,18 and 24 months after surgery
Title
Gastroesophageal reflux
Description
Gastroesophageal reflux assessed by items 5 and 27 of the GIQLI questionnaire
Time Frame
The day before surgery (Day-1) and 6, 12, and 24 months after surgery
Title
Modifications of the gastric and esophageal mucosa
Description
Histological modifications of the gastric and esophageal mucosa, based on upper GI endoscopy with biopsies
Time Frame
2 years after surgery
Title
Frequency of diarrhea
Description
Frequency of diarrhea based on items 7, 30, 31 and 36 of the GIQLI questionnaire
Time Frame
The day before surgery (day-1) and 6, 12, and 24 months after surgery
Title
Nutritional status
Description
Nutritional status, assessed by PTH, vitamin B1, B9, B12, and D levels before and 12 and 24 months after surgery and assessed by hemoglobin, albumin, prealbumin, ferritin, saturation coefficient, before and 6, 12 and 24 months after surgery .
Time Frame
During the period of inclusion (D-60 to D-2) and 6, 12, and 24 months after surgery (The 24-hour steatorrhea will be quantified at 6 months).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged between 18 and 65 years old Morbid obesity with BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 associated with one or more co-morbidities (type 2 diabetes, arterial hypertension, sleep apnea, dyslipidemia, arthritis) Patient who has benefited from an upper GI endoscopy with biopsies Patient who has benefited from a pluridisciplinary evaluation, with a favorable opinion for a gastric bypass Patient who understands and accepts the need for a long term follow-up Patient who agrees to be included in the study and who signs the informed consent form Patient affiliated to a healthcare insurance plan Exclusion Criteria: History of esophagitis on upper GI endoscopy (Los Angeles classification) Severe gastroesophageal reflux disease (GERD), resistant to medical treatment Presence of dysplastic modifications of the gastric mucosa or a history of gastric cancer, on upper gastrointestinal endoscopy. Presence of Helicobacter Pylori resistant to medical treatment Presence of an unhealed gastro-duodenal ulcer or an ulcer diagnosed less than 2 months previously History of previous bariatric surgery (gastric band, sleeve gastrectomy, vertical banded gastroplasty) Presence of a severe and evolutive life threatening pathology, unrelated to obesity Presence of chronic diarrhea (≥ 3 loose or liquid stools per day, over a period of more than 4 weeks) Pregnancy or desire to be pregnant during the study Binge eating disorders or other eating disorders according to DSM V criteria Mentally unbalanced patients, under supervision or guardianship Patient who does not understand French/is unable to give consent Patient not affiliated to a French or European healthcare insurance Patient who has already been included in a trial which has a conflict of interests with the present study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maud ROBERT, MD
Organizational Affiliation
Service de Chirurgie Digestive - Hôpital Edouard Herriot - Hospices Civils de Lyon - France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinique Universitaire de Chirurgie Digestive et de l'Urgence - CHU de Grenoble
City
Grenoble
ZIP/Postal Code
38043
Country
France
Facility Name
Cabinet de chirurgie générale, digestive et de l'obésité - Hôpital Privé Drôme et Ardèche
City
Guilherand-Granges
ZIP/Postal Code
07500
Country
France
Facility Name
Service de Chirurgie Générale et Endocrinienne - Hôpital Claude Huriez - CHU de Lille
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Service de Chirurgie Digestive - Hôpital Edouard Herriot - Hospices Civils de Lyon
City
Lyon
ZIP/Postal Code
69437
Country
France
Facility Name
Service de Chirurgie Digestive et Hépato-Bilio-Pancréatique et Transplantation Hépatique - Hôpital de la Pitié Salpêtrière
City
Paris
ZIP/Postal Code
75013
Country
France
Facility Name
Service de Chirurgie Digestive, Générale et Cancérologique - Hôpital Européen Georges Pompidou - APHP
City
Paris
ZIP/Postal Code
75908
Country
France
Facility Name
Service de Chirurgie Générale - Hôpital Privé de la Loire
City
Saint Etienne
ZIP/Postal Code
42100
Country
France
Facility Name
Service de Chirurgie Digestive et Hépato-Biliaire-Centre Hospitalier Privé Saint Grégoire
City
Saint Grégoire
ZIP/Postal Code
35768
Country
France
Facility Name
Service de Chirurgie Générale, Digestive et Viscérale - Centre Hospitalier Intercommunal de Poissy / Saint Gerrmain en Laye
City
Saint-germain-en-laye
ZIP/Postal Code
78100
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
30851879
Citation
Robert M, Espalieu P, Pelascini E, Caiazzo R, Sterkers A, Khamphommala L, Poghosyan T, Chevallier JM, Malherbe V, Chouillard E, Reche F, Torcivia A, Maucort-Boulch D, Bin-Dorel S, Langlois-Jacques C, Delaunay D, Pattou F, Disse E. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial. Lancet. 2019 Mar 30;393(10178):1299-1309. doi: 10.1016/S0140-6736(19)30475-1. Epub 2019 Mar 6. Erratum In: Lancet. 2019 Mar 30;393(10178):1298.
Results Reference
derived

Learn more about this trial

Omega Loop Versus Roux-en-Y Gastric Bypass

We'll reach out to this number within 24 hrs